keyword
MENU ▼
Read by QxMD icon Read
search

ius levonorgestrel

keyword
https://www.readbyqxmd.com/read/29779566/hormonal-contraception-and-breast-cancer
#1
Carolyn L Westhoff, Malcolm C Pike
The recent Danish cohort study reported a 20% increased risk of breast cancer among current and recent hormonal contraception users. These results are largely consistent with previous studies. This study did not report on stage of disease at diagnosis and it is not clear to what extent the apparent increased risk may be due to a small advance in the timing of diagnosis. This study did not report on the risk associated with the use of a 20-μg ethinyl estradiol pill. They did find an increasing risk in current users of longer duration and an increased risk with use of the levonorgestrel intrauterine system-both of these potentially important findings have not been consistently found in previous studies and require further investigation...
May 17, 2018: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29747214/intestinal-perforation-due-to-deep-infiltrating-endometriosis-during-pregnancy-case-report
#2
Márcia Mendonça Carneiro, Luciana Maria Pyramo Costa, Maria Das Graças Torres, Patrícia Salomé Gouvea, Ivete de Ávila
We report the case of a 33 year-old woman who complained of severe dysmenorrhea since menarche. From 2003 to 2009, she underwent 4 laparoscopies for the treatment of pain associated with endometriosis. After all four interventions, the pain recurred despite the use of gonadotropin-releasing hormone (GnRH) analogues and the insertion of a levonorgestrel intrauterine system (LNG-IUS). Finally, a colonoscopy performed in 2010 revealed rectosigmoid stenosis probably due to extrinsic compression. The patient was advised to get pregnant before treating the intestinal lesion...
April 2018: Revista Brasileira de Ginecologia e Obstetrícia
https://www.readbyqxmd.com/read/29746814/a-case-series-on-the-use-of-levonorgestrel-52mg-intrauterine-system-after-organ-transplant
#3
Cassia R T Juliato, Paulo Stahlscmidt, Arlete Fernandes, Ilza Monteiro, Luis Bahamondes
OBJECTIVE: To assess the clinical performance (pregnancy and occurrence of pelvic infection) of the levonorgestrel 52-mg intrauterine system (LNG IUS) in solid organ transplant recipients. STUDY DESIGN: We performed a retrospective chart review of all patients seen in the Family Planning Clinic at the University of Campinas Department of Obstetrics and Gynecology from 2007-2017 to identify women with solid organ transplantation using immunosuppression who received a LNG- IUS...
May 7, 2018: Contraception
https://www.readbyqxmd.com/read/29715112/low-dose-lng-ius-as-therapy-for-endometrial-hyperplasia-a-prospective-cohort-pilot-study
#4
Elise Thoresen Sletten, Marit Arnes, Anne Beate Vereide, Anne Ørbo
BACKGROUND/AIM: Progestin therapy has been accepted as therapy for low- and medium-risk endometrial hyperplasia. The aim of this study was to investigate the efficacy of the low-dose levonorgestrel-impregnated intrauterine system (LNG-IUS) 13.5 mg (Jaydess®, Bayer Pharmaceuticals, Berlin, Germany) as therapy for endometrial hyperplasia. PATIENTS AND METHODS: A total of 21 women with histologically-verified endometrial hyperplasia were prospectively treated with LNG-IUS Jaydess...
May 2018: Anticancer Research
https://www.readbyqxmd.com/read/29684326/12-month-discontinuation-rates-of-levonorgestrel-intrauterine-system-13-5mg-and-subdermal-etonogestrel-implant-in-adult-women-a-retrospective-claims-database-analysis
#5
Amy Law, Laura Liao, Jay Lin, Avin Yaldo, Richard Lynen
OBJECTIVE: To investigate the 12-month discontinuation rates of levonorgestrel intrauterine system 13.5mg (LNG-IUS 13.5) and subdermal etonogestrel (ENG) implant in the US. STUDY DESIGN: We identified adult women (18-44years) who had an insertion of LNG-IUS 13.5 or ENG implant from the MarketScan Commercial claims database (7/1/2013-9/30/2014). Women were required to have 12months of continuous insurance coverage prior to the insertion (baseline) and at least 12-months after (follow-up)...
April 20, 2018: Contraception
https://www.readbyqxmd.com/read/29656433/antifibrinolytics-for-heavy-menstrual-bleeding
#6
REVIEW
Alison C Bryant-Smith, Anne Lethaby, Cindy Farquhar, Martha Hickey
BACKGROUND: Heavy menstrual bleeding (HMB) is an important physical and social problem for women. Oral treatment for HMB includes antifibrinolytic drugs, which are designed to reduce bleeding by inhibiting clot-dissolving enzymes in the endometrium.Historically, there has been some concern that using the antifibrinolytic tranexamic acid (TXA) for HMB may increase the risk of venous thromboembolic disease. This is an umbrella term for deep venous thrombosis (blood clots in the blood vessels in the legs) and pulmonary emboli (blood clots in the blood vessels in the lungs)...
April 15, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29602870/using-program-data-to-improve-access-to-family-planning-and-enhance-the-method-mix-in-conflict-affected-areas-of-the-democratic-republic-of-the-congo
#7
Lara S Ho, Erin Wheeler
Unmet need for family planning in the conflict-affected area of eastern Democratic Republic of the Congo (DRC) has been reported to be as high as 38%, and women in such conflict settings are often the most at risk for maternal mortality. The International Rescue Committee implements the Family Planning and Post-Abortion Care in Emergencies program in 3 provinces of eastern DRC to provide women and couples access to family planning, including long-acting reversible contraceptives (LARCs). This article presents routine program data from June 2011 through December 2013 from 2 health zones as well as results from a qualitative assessment of family planning clients and of male and female non-users, conducted in 2013...
March 21, 2018: Global Health, Science and Practice
https://www.readbyqxmd.com/read/29579732/development-validation-and-utilization-of-a-highly-sensitive-lc-ms-ms-method-for-quantification-of-levonorgestrel-released-from-a-subdermal-implant-in-human-plasma
#8
Lauren R Cirrincione, Sujan Dilly Penchala, Kimberly K Scarsi, Anthony T Podany, Lee C Winchester, David J Back, Saye H Khoo, Courtney V Fletcher, Marco Siccardi, Laura J Else
Levonorgestrel (LNG) is a synthetic progestin that is available in oral contraceptive tablets, a subdermal implant, and an intrauterine system for contraception. LNG pharmacokinetics are a pivotal determinant of contraceptive efficacy and essential in assessing drug-drug interactions influencing LNG exposure following different routes of LNG administration. A highly sensitive LC-MS/MS method was developed and validated to quantify levonorgestrel in human plasma. Liquid-liquid extraction was utilized with a sample volume of 500 μL to extract levonorgestrel from plasma...
March 12, 2018: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/29560743/bleeding-patterns-for-the-liletta-%C3%A2-levonorgestrel-52-mg-intrauterine-system
#9
Courtney A Schreiber, Stephanie B Teal, Paul D Blumenthal, Lisa M Keder, Andrea I Olariu, Mitchell D Creinin
PURPOSE: Evaluate bleeding patterns for the Liletta® levonorgestrel 52 mg intrauterine system (IUS) using the World Health Organization Belsey definitions. MATERIAL AND METHODS: This prospective multicenter trial evaluates the efficacy and safety of Liletta® (Clinicaltrials.gov NCT00995150). We evaluated bleeding patterns for 1700 nulliparous and multiparous women using a daily diary completed by participants for the first 2 years and by questionnaire every 3 months thereafter...
March 21, 2018: European Journal of Contraception & Reproductive Health Care
https://www.readbyqxmd.com/read/29537321/risk-factors-and-the-choice-of-long-acting-reversible-contraception-following-medical-abortion-effect-on-subsequent-induced-abortion-and-unwanted-pregnancy
#10
Riina Korjamo, Oskari Heikinheimo, Maarit Mentula
OBJECTIVE: To analyse the post-abortion effect of long-acting reversible contraception (LARC) plans and initiation on the risk of subsequent unwanted pregnancy and abortion. MATERIALS AND METHODS: retrospective cohort study of 666 women who underwent medical abortion between January-May 2013 at Helsinki University Hospital, Finland. Altogether 159 (23.8%) women planning post-abortion use of levonorgestrel-releasing intrauterine system (LNG-IUS) participated in a randomized study and had an opportunity to receive the LNG-IUS free-of-charge from the hospital...
April 2018: European Journal of Contraception & Reproductive Health Care
https://www.readbyqxmd.com/read/29530557/-endometriosis-medical-treatment-hormonal-treatment-for-the-management-of-pain-and-endometriotic-lesions-recurrence-cngof-has-endometriosis-guidelines
#11
S Geoffron, J Cohen, M Sauvan, G Legendre, J M Wattier, E Daraï, H Fernandez, N Chabbert-Buffet
The available literature, from 2006 to 2017, on hormonal treatment has been analysed as a contribution to the HAS-CNGOF task force for the treatment of endometriosis. Available data are heterogeneous and the general level of evidence is moderate. Hormonal treatment is usually offered as the primary option to women suffering from endometriosis. It cannot be used in women willing to conceive. In women who have not been operated, the first line of hormonal treatment includes combined oral contraceptives (COC) and the levonorgestrel-releasing intra uterine system (52mg LNG-IUS)...
March 2018: Gynecologie, Obstetrique, Fertilite & Senologie
https://www.readbyqxmd.com/read/29510966/-medical-treatment-for-the-management-of-painful-endometriosis-without-infertility-cngof-has-endometriosis-guidelines
#12
M Sauvan, N Chabbert-Buffet, M Canis, P Collinet, X Fritel, S Geoffron, G Legendre, J-M Wattier, H Fernandez
OBJECTIVE: To provide clinical practice guidelines for the management of painful endometriosis in women without infertility. METHODS: Systematic review of the literature literature since 2006, level of evidence rating, external proofreading and grading of the recommendation grade by an expert group according to HAS methodology. RESULTS: Combined hormonal contraceptives (COP) and the levonorgestrel-releasing intra-uterin system (LNG-IUS) are recommended as first-line hormonal therapies for the treatment of painful endometriosis (grade B)...
March 2018: Gynecologie, Obstetrique, Fertilite & Senologie
https://www.readbyqxmd.com/read/29486748/levonorgestrel-releasing-intrauterine-system-for-treatment-of-heavy-menstrual-bleeding-in-adolescents-with-glanzmann-s-thrombasthenia-illustrated-case-series
#13
Meiqiu Lu, Xin Yang
BACKGROUND: Glanzmann's Thrombasthenia (GT) is an inherited genetic disorder caused by defects in the platelet membrane glycoproteins IIb/IIIA, and is associated with heavy menstrual bleeding (HMB). HMB is a common complication in female patients, and many adolescent girls with this disease have issues with HMB beginning at menarche. The available treatment modalities including anti-fibrinolytics, nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal therapies though are effective, their associated side effects, limited efficacy and the poor compliance is a challenge in management of HMB...
February 27, 2018: BMC Women's Health
https://www.readbyqxmd.com/read/29483855/the-role-of-levonorgestrel-intrauterine-systems-in-the-treatment-of-symptomatic-fibroids
#14
REVIEW
Wojciech Wrona, Anna Stępniak, Piotr Czuczwar
Uterine fibroids are considered to be the most frequently occurring tumours in females. The majority of fibroids do not require any treatment. When symptomatic, the major ailments include abnormal uterine bleeding, painful menstruation, pelvic pressure or pain, urinary problems, constipation, infertility, and recurrent pregnancy loss. Surgery remains a mainstay of symptomatic uterine fibroids therapy; however, minimally-invasive techniques and pharmacological management have become more available. The levonorgestrel intrauterine system (LNG-IUS) is a T-shaped device with a vertical stem containing a reservoir of levonorgestrel and is widely known for its contraception effect...
December 2017: Przeglad Menopauzalny, Menopause Review
https://www.readbyqxmd.com/read/29482839/levonorgestrel-releasing-intrauterine-system-use-is-associated-with-a-decreased-risk-of-ovarian-and-endometrial-cancer-without-increased-risk-of-breast-cancer-results-from-the-nowac-study
#15
Mie Jareid, Jean-Christophe Thalabard, Morten Aarflot, Hege M Bøvelstad, Eiliv Lund, Tonje Braaten
OBJECTIVE: Women with ovarian cancer have poor survival rates, which have proven difficult to improve; therefore primary prevention is important. The levonorgestrel-releasing intrauterine system (LNG-IUS) prevents endometrial cancer, and recent studies suggested that it may also prevent ovarian cancer, but with a concurrent increased risk of breast cancer. We compared adjusted risks of ovarian, endometrial, and breast cancer in ever users and never users of LNG-IUS. METHODS: Our study cohort consisted of 104,318 women from the Norwegian Women and Cancer Study, 9144 of whom were ever users and 95,174 of whom were never users of LNG-IUS...
April 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29462709/postinsertional-pain-after-intrauterine-device-placement-among-nulliparous-adolescents
#16
K M Sinning, D C Jude, J L Yoost
STUDY OBJECTIVE: To quantify the "normal" adolescent experience after intrauterine device insertion, to provide appropriate counseling for future adolescents. DESIGN: Prospective cohort study. SETTING: Marshall University Department of Obstetrics and Gynecology generalist and adolescent gynecology clinics. PARTICIPANTS: Nulliparous adolescents age 13-18 years and parous adults 18 years of age or older who received a levonorgestrel intrauterine system (LNG-IUS)...
February 17, 2018: Journal of Pediatric and Adolescent Gynecology
https://www.readbyqxmd.com/read/29458902/postoperative-maintenance-levonorgestrel-releasing-intrauterine-system-for-symptomatic-uterine-adenomyoma
#17
Ching-Jung Lin, Teh-Fu Hsu, Yen-Hou Chang, Ben-Shian Huang, Ling-Yu Jiang, Peng-Hui Wang, Yi-Jen Chen
OBJECTIVE: To evaluate whether a maintenance levonorgestrel-releasing intrauterine system is effective for preventing the recurrence of postoperative adenomyosis-related symptoms. MATERIALS AND METHODS: From January 2005 through December 2014, a retrospective study including 133 patients with symptomatic adenomyosis undergoing conservative uterine-sparing surgery followed by gonadotropin-releasing hormone agonist treatment was conducted. We excluded the 18 patients who did not meet the inclusion criteria...
February 2018: Taiwanese Journal of Obstetrics & Gynecology
https://www.readbyqxmd.com/read/29458551/short-and-long-term-influence-of-the-levonorgestrel-releasing-intrauterine-system-mirena%C3%A2-on-vaginal-microbiota-and-candida
#18
Gilbert Gerard Ghislain Donders, G Bellen, Kateryna Ruban, Ben Van Bulck
BACKGROUND: Recurrent vulvovaginal infections are a frequent complaint in young women in need of contraception. However, the influence of the contraceptive method on the course of the disease is not well known. AIM: To investigate the influence of the levonorgestrel-releasing intrauterine-system (LNG-IUS) on the vaginal microflora. METHODS: Short-term (3 months) and long-term (1 to 5 years) changes of vaginal microbiota were compared with pre-insertion values in 252 women presenting for LNG-IUS insertion...
March 2018: Journal of Medical Microbiology
https://www.readbyqxmd.com/read/29449327/kyleena-another-levonorgestrel-ius
#19
(no author information available yet)
A levonorgestrel (LNG) intrauterine system (IUS) known as Kyleena (Bayer PLC) received marketing authorisation from the European Medicines Agency in 2016.1 The device contains 19.5mg LNG and is licensed for contraception for up to 5 years. This is the fourth LNG IUS product to be licensed for use in the UK. The company states that Kyleena offers advantages over Mirena and Jaydess LNG IUS devices.2 Here we consider the evidence for Kyleena.
February 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29436865/sexual-function-and-quality-of-life-of-women-adopting-the-levonorgestrel-releasing-intrauterine-system-lng-ius-13-5-mg-after-abortion-for-unintended-pregnancy
#20
Salvatore Caruso, Stefano Cianci, Salvatore Giovanni Vitale, Valentina Fava, Silvia Cutello, Antonio Cianci
PURPOSE: The aim of the study was to investigate the impact of the long-acting reversible contraception (LARC) levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) on sexual function and quality of life (QoL) in women after having undergone abortion for unintended pregnancy. METHODS: In a prospective controlled study, 128 women aged 16-35 years received counseling to adopt LNG-IUS contraception after termination of pregnancy. The Visual Analog Scale (VAS), the Short Form-36 questionnaire (SF-36), the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to investigate, respectively, pelvic pain levels, QoL, sexual function and sexual distress of these women at baseline (T0) and at 6 (T1) and 12 (T2) months after LNG-IUS placement...
February 2018: European Journal of Contraception & Reproductive Health Care
keyword
keyword
70416
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"